TG THERAPEUTICS, INC. Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss
TG THERAPEUTICS, INC. (TGTX) had Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss of $129.68 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets
us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss · last filed 2026-08-05
- 2026-06-30: Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss $129.68M.
- 2026-03-31: Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss $130.63M.
- 2025-12-31: Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss $120.36M.
- 2025-09-30: Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss $104.23M.
| Period end | Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss | Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss as first filed |
|---|---|---|
| 2026-06-30 | $129.68M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $130.63M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $120.36M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $104.23M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $149.73M 10-Q · filed 2025-08-08 | |
| 2025-03-31 | $144.10M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $131.11M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $145.22M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $134.34M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $131.11M 10-Q · filed 2025-05-09 | $134.31M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $124.58M 10-K · filed 2025-03-03 | |
| 2022-12-31 | $71.78M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |